{"schema_version":"secwatch.filing_event.v1","accession":"0001736730-26-000015","form_type":"8-K","ticker":"CAMP","cik":"0001736730","company_name":"Camp4 Therapeutics Corp","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.033836+00:00","generated_at":"2026-05-15T19:45:55.363422+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CAMP4 FY2025 net loss $80.4M; cash runway into 2028, GSK deal, SYNGAP1 progress","bullets":["Net loss of $80.4M in FY2025 vs $51.8M in FY2024, driven by $29.8M non-cash loss on derivative tranche liability.","Cash and equivalents $109.5M (Dec 31, 2025), up from $64.0M; cash runway extended into 2028.","GSK collaboration: $17.5M upfront, up to $440M in milestones plus tiered royalties for ASO candidates in neurodegenerative and kidney diseases.","GLP tox studies for CMP-002 ongoing; global Phase 1/2 trial in SYNGAP1 patients expected as early as H2 2026.","Paused development of CMP-001 and exploring partnership opportunities for that program."],"urls":{"canonical":"https://secwatch.observer/filing/0001736730-26-000015","json":"https://secwatch.observer/filing/0001736730-26-000015.json","markdown":"https://secwatch.observer/filing/0001736730-26-000015.md","text":"https://secwatch.observer/filing/0001736730-26-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736730/000173673026000015/0001736730-26-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736730/000173673026000015/camp-20260305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:45:55.363422+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60a8af2881af4cd4e1c89ab44c0757fb01db4c2d","claim":"Camp4 Therapeutics Corp reported the year ended December 31, 2025 results: net income $80.4 million.","evidence_excerpt":"Net loss for the year ended December 31, 2025, was $80.4 million compared to $51.8 million for the year ended December 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1736730/000173673026000015/0001736730-26-000015-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Net income","value":"$80.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}